Idarucizumab for the treatment of dabigatran-related nephropathy [PDF]
Clinical Kidney Journal, 2020 Abstract Anticoagulant-related nephropathy (ARN) is a clinical syndrome of acute kidney injury in patients taking vitamin K antagonists or direct oral anticoagulants. It is associated with increased mortality and there is no specific treatment. We report the case of a 78-year-old man on dabigatran who developed macroscopic haematuria and
Ammar Alsamarrai +2 more
openaire +3 more sources
Frontiers in Neurology, 2021 Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran.
Senta Frol +4 more
doaj +1 more source
Teendők súlyos vérzés vagy sürgős sebészeti beavatkozás esetén direkt orális antikoaguláns gyógyszerrel kezeltekben. Az új dabigatran-antidótum: idarucizumab helye a klinikai gyakorlatban [PDF]
, 2016 Absztrakt Az elmúlt hat évtizedben csak a K-vitamin-antagonista kumarinokat alkalmazhattuk orális antikoagulánsként.
Boda, Zoltán
core +1 more source
Future Science OA, 2021 Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.
Eran Kalmanovich +12 more
doaj +1 more source
Activated prothrombin complex in the management of direct thrombin inhibitor-associated intracerebral haemorrhage. [PDF]
, 2006 Intracerebral haematoma expansion independently predicts poor functional outcome and mortality. Therefore, it is important to act quickly to arrest this expansion.
Abeysinghe, C +7 more
core +4 more sources
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases [PDF]
, 2017 Non-vitamin K antagonist oral anticoagulants (NOACs) have a favorable benefit-risk profile compared with vitamin K antagonists. However, the lack of specific reversal agents has made the management of some patients receiving long-term treatment with ...
Bocksrucker, Christof +9 more
core +4 more sources
Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]
, 2017 A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto +2 more
core +2 more sources
Real-world experience with reversal of dabigatran by idarucizumab [PDF]
Thrombosis Research, 2021 Idarucizumab reverses the anticoagulant effect of dabigatran. We aimed to investigate real-world experience with idarucizumab and associated clinical outcomes.We conducted a retrospective observational case series on dabigatran users treated with idarucizumab.
Haastrup, Simone Bonde +4 more
openaire +7 more sources
Managing patients taking novel oral anticoagulants (NOAs) in dentistry: A discussion paper on clinical implications [PDF]
, 2016 Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors ...
Costantinides, Fulvia +3 more
core +1 more source
Journal of Medical Case Reports, 2019 Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani +3 more
doaj +1 more source